Caseware UK (AP4) 2024.0.164 2024.0.164 2025-04-302025-04-3023No description of principal activity2024-05-01falsetruetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 06980862 2024-05-01 2025-04-30 06980862 2023-05-01 2024-04-30 06980862 2025-04-30 06980862 2024-04-30 06980862 c:Director2 2024-05-01 2025-04-30 06980862 d:FurnitureFittings 2024-05-01 2025-04-30 06980862 d:FurnitureFittings 2025-04-30 06980862 d:FurnitureFittings 2024-04-30 06980862 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-05-01 2025-04-30 06980862 d:ComputerEquipment 2024-05-01 2025-04-30 06980862 d:ComputerEquipment 2025-04-30 06980862 d:ComputerEquipment 2024-04-30 06980862 d:ComputerEquipment d:OwnedOrFreeholdAssets 2024-05-01 2025-04-30 06980862 d:OwnedOrFreeholdAssets 2024-05-01 2025-04-30 06980862 d:CurrentFinancialInstruments 2025-04-30 06980862 d:CurrentFinancialInstruments 2024-04-30 06980862 d:CurrentFinancialInstruments d:WithinOneYear 2025-04-30 06980862 d:CurrentFinancialInstruments d:WithinOneYear 2024-04-30 06980862 d:ShareCapital 2025-04-30 06980862 d:ShareCapital 2024-04-30 06980862 d:RetainedEarningsAccumulatedLosses 2025-04-30 06980862 d:RetainedEarningsAccumulatedLosses 2024-04-30 06980862 c:OrdinaryShareClass1 2024-05-01 2025-04-30 06980862 c:OrdinaryShareClass1 2025-04-30 06980862 c:OrdinaryShareClass1 2024-04-30 06980862 c:FRS102 2024-05-01 2025-04-30 06980862 c:AuditExempt-NoAccountantsReport 2024-05-01 2025-04-30 06980862 c:FullAccounts 2024-05-01 2025-04-30 06980862 c:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 06980862 e:PoundSterling 2024-05-01 2025-04-30 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 06980862









PHARMAWISE LTD







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 APRIL 2025

 
PHARMAWISE LTD
REGISTERED NUMBER: 06980862

STATEMENT OF FINANCIAL POSITION
AS AT 30 APRIL 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 4 
14,105
14,498

  
14,105
14,498

Current assets
  

Debtors: amounts falling due within one year
 5 
26,177
68,518

Cash at bank and in hand
 6 
24
263

  
26,201
68,781

Creditors: amounts falling due within one year
 7 
(38,988)
(33,407)

Net current (liabilities)/assets
  
 
 
(12,787)
 
 
35,374

Total assets less current liabilities
  
1,318
49,872

  

Net assets
  
1,318
49,872


Capital and reserves
  

Called up share capital 
 8 
100
100

Profit and loss account
  
1,218
49,772

  
1,318
49,872


Page 1

 
PHARMAWISE LTD
REGISTERED NUMBER: 06980862
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 30 APRIL 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




P Mendelsohn
Director

Date: 16 January 2026

The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
PHARMAWISE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025

1.


General information

Pharmawise Ltd is a private company limited by shares and incorporated in England and Wales.  Its registered number is 06980862 and its registered address is 101 New Cavendish Street, 1st Floor South London, United Kingdom, W1W 6XH.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.4

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds.

Page 3

 
PHARMAWISE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025

2.Accounting policies (continued)

 
2.5

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Fixtures and fittings
-
25%
Straight line
Computer equipment
-
33%
Striaght line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.6

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.7

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.9

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 3 (2024 - 2).

Page 4

 
PHARMAWISE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025

4.


Tangible fixed assets





Fixtures and fittings
Computer equipment
Total

£
£
£



Cost or valuation


At 1 May 2024
22,556
20,548
43,104


Additions
-
6,022
6,022



At 30 April 2025

22,556
26,570
49,126



Depreciation


At 1 May 2024
12,833
15,773
28,606


Charge for the year on owned assets
2,483
3,932
6,415



At 30 April 2025

15,316
19,705
35,021



Net book value



At 30 April 2025
7,240
6,865
14,105



At 30 April 2024
9,723
4,775
14,498

Page 5

 
PHARMAWISE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025

5.


Debtors

2025
2024
£
£


Trade debtors
16,177
46,726

Other debtors
-
21,792

Prepayments and accrued income
10,000
-

26,177
68,518



6.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
24
263

Less: bank overdrafts
(21,185)
(14,293)

(21,161)
(14,030)



7.


Creditors: Amounts falling due within one year

2025
2024
£
£

Bank overdrafts
21,185
14,293

Trade creditors
7,059
9,148

Amounts owed to group undertakings
540
540

Other taxation and social security
2,593
1,490

Other creditors
1,111
614

Accruals and deferred income
6,500
7,322

38,988
33,407



8.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



100 (2024 - 100) Ordinary Shares of £1.00 each
100
100


 
Page 6